Download PDFPDF
EP795 Searching for the best maintenance therapy in platinum-sensitive recurrent ovarian cancer: bevacizumab or PARP-inhibitors? A network meta-analysis
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you don't have an account you can just enter your email address in the email box below.
Sign In to Email Alerts with your Email Address